Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: the HomeGuide Registry

Renato Pietro Ricci, Loredana Morichelli, Antonio D'Onofrio, Leonardo Calò, Diego Vaccari, Gabriele Zanotto, Antonio Curnis, Gianfranco Buja, Nicola Rovai, Alessio Gargaro, Renato Pietro Ricci, Loredana Morichelli, Antonio D'Onofrio, Leonardo Calò, Diego Vaccari, Gabriele Zanotto, Antonio Curnis, Gianfranco Buja, Nicola Rovai, Alessio Gargaro

Abstract

Aims: The HomeGuide Registry was a prospective study (NCT01459874), implementing a model for remote monitoring of cardiac implantable electronic devices (CIEDs) in daily clinical practice, to estimate effectiveness in major cardiovascular event detection and management.

Methods and results: The workflow for remote monitoring [Biotronik Home Monitoring (HM)] was based on primary nursing: each patient was assigned to an expert nurse for management and to a responsible physician for medical decisions. In-person visits were scheduled once a year. Seventy-five Italian sites enrolled 1650 patients [27% pacemakers, 27% single-chamber implantable cardioverter defibrillators (ICDs), 22% dual-chamber ICDs, 24% ICDs with cardiac resynchronization therapy]. Population resembled the expected characteristics of CIED patients. During a 20 ± 13 month follow-up, 2471 independently adjudicated events were collected in 838 patients (51%): 2033 (82%) were detected during HM sessions; 438 (18%) during in-person visits. Sixty were classified as false-positive, with generalized estimating equation-adjusted sensitivity and positive predictive value of 84.3% [confidence interval (CI), 82.5-86.0%] and 97.4% (CI, 96.5-98.2%), respectively. Overall, 95% of asymptomatic and 73% of actionable events were detected during HM sessions. Median reaction time was 3 days [interquartile range (IQR), 1-14 days]. Generalized estimating equation-adjusted incremental utility, calculated according to four properties of major clinical interest, was in favour of the HM sessions: +0.56 (CI, 0.53-0.58%), P < 0.0001. Resource consumption: 3364 HM sessions performed (76% by nurses), median committed monthly manpower of 55.5 (IQR, 22.0-107.0) min × health personnel/100 patients.

Conclusion: Home Monitoring was highly effective in detecting and managing clinical events in CIED patients in daily practice with remarkably low manpower and resource consumption.

Keywords: Implantable cardioverter defibrillators; Pacemakers; Remote monitoring; Telemedicine.

Figures

Figure 1
Figure 1
HomeGuide model workflow with action items and responsibilities. EP, electrophysiology/cardiac pacing laboratory; ICD, implantable cardioverter defibrillator; HM, Home Monitoring; PM, Pacemaker; RN, responsible nurse; RP, responsible physician.
Figure 2
Figure 2
Generalized estimating equation-adjusted overall HM sensitivity, PPV, and IU. Home Monitoring sensitivity estimates for subgroups of MCEs are also displayed.GEE, generalized estimating equation; HM, Home Monitoring.

References

    1. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm. 2008;5:907–25.
    1. Dubner S, Auricchio A, Steinberg JS, Vardas P, Stone P, Brugada J, et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs) Europace. 2012;14:278–93.
    1. Varma N, Epstein A, Irimpen A, Schweikert R, Shah J, Love CJ. TRUST Investigators. Efficacy and safety of automatic remote monitoring for ICD follow-up: The TRUST trial. Circulation. 2010;122:325–32.
    1. Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH. CONNECT Investigators. The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011;57:1181–9.
    1. Landolina M, Perego GB, Lunati M, Curnis A, Guenzati G, Vicentini A, et al. Remote monitoring reduces healthcare utilization and improves quality of care in heart failure patients with implantable defibrillators: The EVOLVO (Evolution Of Management Strategies Of Heart Failure Patients With Implantable Defibrillators) Study. Circulation. 2012;125:2985–92.
    1. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace. 2009;11:54–61.
    1. Mabo P, Victor F, Bazin P, Ahres S, Babuty D, Da Costa A, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial) Eur Heart J. 2012;33:1105–11.
    1. Ricci RP, Morichelli L, Santini M. Home monitoring remote control of pacemaker and implantable cardioverter defibrillator patients in clinical practice: impact on medical management and health-care resource utilization. Europace. 2008;10:164–70.
    1. Varma N, Stambler B, Chun S. Detection of atrial fibrillation by implanted devices with wireless data transmission capability. Pacing Clin Electrophysiol. 2005;28(Suppl. 1):S133–6.
    1. Lazarus A. Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: analysis of a worldwide database. Pacing Clin Electrophysiol. 2007;30(Suppl. 1):S2–12.
    1. Ricci RP, Calcagnini G, Castro A, Giada F, Igidbashan D, Landolina M, et al. Consensus document on remote monitoring of cardiac implantable electronic devices: technology, indications, organizational models, acceptability, responsibility, and economic issues. G Ital Cardiol. 2011;12:450–67.
    1. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–38.
    1. Spencker S, Coban N, Koch L, Schirdewan A, Muller D. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. Europace. 2009;11:483–8.
    1. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-Up (TRUST) trial. Circ Arrhythm Electrophysiol. 2010;3:428–36.
    1. Ricci RP, Morichelli L, Gargaro A, Laudadio MT, Santini M. Home monitoring in patients with implantable cardiac devices: is there a potential reduction of stroke risk? Results from a computer model tested through Monte Carlo simulations. J Cardiovasc Electrophysiol. 2009;20:1244–51.
    1. Guédon-Moreaul L, Lacroix D, Sadoul N, Clémenty J, Kouakam C, Hermida JS, et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial. Eur Heart J. 2012 [EPUB ahead of prt].
    1. Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J. 2009;158:364–70.
    1. Sack S, Wende CM, Nägele H, Katz A, Bauer WR, Barr CS, et al. Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (Home monitoring in cardiac resynchronization therapy) study. Eur J Heart Fail. 2011;13:1019–27.
    1. Whellan DJ, Ousdigian KT, Al-Khatib SM, Pu W, Sarkar S, Porter CB, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to access and review trending information and evaluate correlation to symptoms in patients with heart failure) study. J Am Coll Cardiol. 2010;55:1803–10.
    1. Elsner CH, Sommer P, Piorkowski C, Taborsky M, Neuser H, Bytesnik J, et al. A prospective multicenter comparison trial of home monitoring against regular follow-up in MADIT II patients: additional visits and cost impact. Comput Cardiol. 2006;33:241–4.

Source: PubMed

3
Sottoscrivi